Interim report for Q3 2016
In the third quarter we report a continued positive trend in sales of our own portfolio of infection prevention products for the healthcare sector. We have delivered a total of approx. 284,000 products so far this year, an increase by approx. 260 percent. This means that we are already now close to our goal of at least doubling the full-year volumes from 2015. Combined with stable license revenues and costs under control, this means that we can deliver an EBITDA margin of 28 percent in the quarter.Third Quarter (July-September 2016) · During the third quarter, a total of approx. 87,